Risk of breast cancer in risperidone users: A nationwide cohort study

Schizophrenia Research

Volumn 182, Issue , 2017, Pages 98-103

  Reutfors, Johan ^a   Wingård, Louise ^a   Brandt, Lena ^a   Wang, Yiting ^b   Qiu, Hong ^b   Kieler, Helle ^a   Bahmanyar, Shahram ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b JANSSEN RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Antipsychotics; Atypical antipsychotics; Breast cancer; Cohort study; Risperidone

Indexed keywords

ATYPICAL ANTIPSYCHOTIC AGENT; NEUROLEPTIC AGENT; PALIPERIDONE; RISPERIDONE;

ADULT; AGE DISTRIBUTION; AGED; ARTICLE; BREAST CANCER; CANCER DIAGNOSIS; CANCER REGISTRY; CANCER RISK; CANCER STAGING; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG USE; FEMALE; FOLLOW UP; HUMAN; MIDDLE AGED; PROSPECTIVE STUDY; RISK ASSESSMENT; SWEDEN; ADOLESCENT; BREAST TUMOR; CHEMICALLY INDUCED; MENTAL DISEASE; RISK FACTOR; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGE DISTRIBUTION; AGED; AGED, 80 AND OVER; ANTIPSYCHOTIC AGENTS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MENTAL DISORDERS; MIDDLE AGED; RISK FACTORS; RISPERIDONE; TREATMENT OUTCOME; YOUNG ADULT;

EID: 85006136332     PISSN: 09209964     EISSN: 15732509     Source Type: Journal    
DOI: 10.1016/j.schres.2016.10.035     Document Type: Article

References (31)

1. Ajmal, A., Joffe, H., Nachtigall, L.B., Psychotropic-induced hyperprolactinemia: a clinical review. Psychosomatics 55:1 (2014), 29–36.
2. Azoulay, L., Yin, H., Renoux, C., Suissa, S., The use of atypical antipsychotics and the risk of breast cancer. Breast Cancer Res. Treat. 129:2 (2011), 541–548.
3. Berinder, K., Akre, O., Granath, F., Hulting, A.L., Cancer risk in hyperprolactinemia patients: a population-based cohort study. Eur. J. Endocrinol. 165:2 (2011), 209–215.
4. Biller, B.M., Baum, H.B., Rosenthal, D.I., Saxe, V.C., Charpie, P.M., Klibanski, A., Progressive trabecular osteopenia in women with hyperprolactinemic amenorrhea. J. Clin. Endocrinol. Metab. 75:3 (1992), 692–697.
5. Brugmans, J., Verbruggen, F., Dom, J., Schuermans, V., Prolactin, phenothiazines, admission to mental hospital, and carcinoma of the breast. Lancet 2:7827 (1973), 502–503.
6. Dalton, S.O., Johansen, C., Poulsen, A.H., Norgaard, M., Sorensen, H.T., McLaughlin, J.K., et al. Cancer risk among users of neuroleptic medication: a population-based cohort study. Br. J. Cancer 95:7 (2006), 934–939.
7. Dekkers, O.M., Ehrenstein, V., Bengtsen, M., Farkas, D.K., Pereira, A.M., Sorensen, H.T., et al. Breast cancer risk in hyperprolactinemia: a population-based cohort study and meta-analysis of the literature. Eur. J. Endocrinol. 173:2 (2015), 269–273.
8. Edge, S.B., Carlson, R.W., 2011. Breast cancer staging: predicting outcome and response to treatment, Breast Surg. Tech. Interdisc. Manag. Springer, pp. 269–285.
9. Froes Brandao, D., Strasser-Weippl, K., Goss, P.E., Prolactin and breast cancer: the need to avoid undertreatment of serious psychiatric illnesses in breast cancer patients: a review. Cancer 122:2 (2016), 184–188.
10. Haddad, P.M., Wieck, A., Antipsychotic-induced hyperprolactinaemia: mechanisms, clinical features and management. Drugs 64:20 (2004), 2291–2314.
11. Harvey, P.W., Human relevance of rodent prolactin-induced non-genotoxic mammary carcinogenesis: prolactin involvement in human breast cancer and significance for toxicology risk assessments. J. Appl. Toxicol. 25:3 (2005), 179–183.
12. Harvey, P.W., Hypothesis: prolactin is tumorigenic to human breast: dispelling the myth that prolactin-induced mammary tumors are rodent-specific. J. Appl. Toxicol. 32:1 (2012), 1–9.
13. Helzlsouer, K.J., Alberg, A.J., Bush, T.L., Longcope, C., Gordon, G.B., Comstock, G.W., A prospective study of endogenous hormones and breast cancer. Cancer Detect. Prev. 18:2 (1994), 79–85.
14. Kabuto, M., Akiba, S., Stevens, R.G., Neriishi, K., Land, C.E., A prospective study of estradiol and breast cancer in Japanese women. Cancer Epidemiol. Biomark. Prev. 9:6 (2000), 575–579.
15. Kanhouwa, S., Gowdy, J.M., Solomon, J.D., Phenothiazines and breast cancer. J. Natl. Med. Assoc. 76:8 (1984), 785–788.
16. Kelly, J.P., Rosenberg, L., Palmer, J.R., Rao, R.S., Strom, B.L., Stolley, P.D., et al. Risk of breast cancer according to use of antidepressants, phenothiazines, and antihistamines. Am. J. Epidemiol. 150:8 (1999), 861–868.
17. Ludvigsson, J.F., Andersson, E., Ekbom, A., Feychting, M., Kim, J.L., Reuterwall, C., et al. External review and validation of the Swedish national inpatient register. BMC Public Health, 11, 2011, 450.
18. Manjer, J., Johansson, R., Berglund, G., Janzon, L., Kaaks, R., Agren, A., et al. Postmenopausal breast cancer risk in relation to sex steroid hormones, prolactin and SHBG (Sweden). Cancer Causes Control 14:7 (2003), 599–607.
19. Mattsson, B., Rutqvist, L.E., Some aspects on validity of breast cancer, pancreatic cancer and lung cancer registration in Swedish official statistics. Radiother. Oncol. 4:1 (1985), 63–70.
20. Nilsson, L., Petersson, C., Consumption of psychopharmaceuticals in residential facilities for the elderly. Evaluation of the extent, indications and effects. Lakartidningen 98:12 (2001), 1371–1373.
21. Nitze, L.M., Galsgaard, E.D., Din, N., Lund, V.L., Rasmussen, B.B., Berchtold, M.W., et al. Reevaluation of the proposed autocrine proliferative function of prolactin in breast cancer. Breast Cancer Res. Treat. 142:1 (2013), 31–44.
22. Park, Y.M., Lee, S.H., Lee, B.H., Lee, K.Y., Lee, K.S., Kang, S.G., et al. Prolactin and macroprolactin levels in psychiatric patients receiving atypical antipsychotics: a preliminary study. Psych. Res. 239 (2016), 184–189.
23. Reynolds, C., Montone, K.T., Powell, C.M., Tomaszewski, J.E., Clevenger, C.V., Expression of prolactin and its receptor in human breast carcinoma. Endocrinology 138:12 (1997), 5555–5560.
24. Siegel, R., Ma, J., Zou, Z., Jemal, A., Cancer statistics, 2014. CA Cancer J. Clin. 64:1 (2014), 9–29.
25. Tikk, K., Sookthai, D., Johnson, T., Rinaldi, S., Romieu, I., Tjonneland, A., et al. Circulating prolactin and breast cancer risk among pre- and postmenopausal women in the EPIC cohort. Ann. Oncol. 25:7 (2014), 1422–1428.
26. Touraine, P., Martini, J.F., Zafrani, B., Durand, J.C., Labaille, F., Malet, C., et al. Increased expression of prolactin receptor gene assessed by quantitative polymerase chain reaction in human breast tumors versus normal breast tissues. J. Clin. Endocrinol. Metab. 83:2 (1998), 667–674.
27. Tworoger, S.S., Eliassen, A.H., Zhang, X., Qian, J., Sluss, P.M., Rosner, B.A., et al. A 20-year prospective study of plasma prolactin as a risk marker of breast cancer development. Cancer Res. 73:15 (2013), 4810–4819.
28. Wagner, S., Mantel, N., Breast cancer at a psychiatric hospital before and after the introduction of neuroleptic agents. Cancer Res. 38:9 (1978), 2703–2708.
29. Wang, D.Y., De Stavola, B.L., Bulbrook, R.D., Allen, D.S., Kwa, H.G., Fentiman, I.S., et al. Relationship of blood prolactin levels and the risk of subsequent breast cancer. Int. J. Epidemiol. 21:2 (1992), 214–221.
30. Wang, P.S., Walker, A.M., Tsuang, M.T., Orav, E.J., Glynn, R.J., Levin, R., et al. Dopamine antagonists and the development of breast cancer. Arch. Gen. Psychiatry 59:12 (2002), 1147–1154.
31. Wettermark, B., Hammar, N., Fored, C.M., Leimanis, A., Otterblad Olausson, P., Bergman, U., et al. The new Swedish prescribed drug register–opportunities for pharmacoepidemiological research and experience from the first six months. Pharmacoepidemiol. Drug Saf. 16:7 (2007), 726–735.